• Explore /
  • Poster
  • / Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Abstract Poster

Authors

null

Charles S. Fuchs

Dana-Farber Cancer Institute, Boston, MA

Charles S. Fuchs , Andrew E. Denker , Josep Tabernero , Eric Van Cutsem , Atsushi Ohtsu , Baohoang Lam , Minori Koshiji , Yung-Jue Bang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02335411

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS4135)

DOI

10.1200/jco.2015.33.15_suppl.tps4135

Abstract #

TPS4135

Poster Bd #

245a

Abstract Disclosures

Similar Posters

First Author: Charles S. Fuchs

First Author: Timothy Jay Price

First Author: Manish A. Shah

First Author: Farshid Dayyani